Sorin Group - Cardiac Rhythm Management (CRM)

Sorin Group is a worldwide leader in the design, manufacture and marketing of Cardiac Rhythm Management (CRM) systems. Sorin Group’s therapeutic solutions cover the entire spectrum of cardiac rhythm disorders.

• Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) and ventricular CRT leads for the management of Heart Failure (HF)
• Implantable Cardioverter Defibrillators (ICDs) and defibrillation leads for tachyarrhythmia management
• Cardiac pacemakers and pacing leads for bradyarrhythmia management

Sorin Group has been at the heart of medical technology for over 50 years. Sorin Group’s pioneering breakthroughs have improved the lives of countless patients around the world. Cardiac rhythm management systems are designed and built to save lives, and Sorin Group strives for the highest levels of performance and quality.

CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATORS (CRT-D)

In patients with poor ventricular function, there is a high incidence of slow Ventricular Tachycardias (VT) and these arrhythmias have significant clinical effects. A recent publication indicated that not maintaining CRT during exercise might not allow the patient to experience prolonged, and eventually beneficial, physical activity.

Thanks to OVATIO™ CRT 6750’s unique BTO™ (Brady-Tachy Overlap1) feature, designed to ‘unlock pacing and detection’, patients are delivered resynchronization therapy during exercise. This solution allows for the detection and painless ATP therapy for slow VTs with rates as low as 100bpm while still maintaining cardiac resynchronization therapy up to 145bpm.

With its new shape and smooth contours, only 11mm thick and 30cm³ in volume, OVATIO™ CRT 6750 is our smallest CRT available today.

IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD)

The OVATIO™ ICD family includes innovative features dedicated to both pacing and arrhythmia management. OVATIO™ DR, the dual chamber ICD includes two exciting features: SafeR™ and PARAD®+.

SafeR™ promotes natural heart activity by reducing unnecessary stimulation in the right ventricle. Studies suggest that this reduction could decrease the risk of heart failure and atrial fibrillation, both of which can prove fatal.

PARAD®+ is intended to protect patients from inappropriate shocks which can result from misclassified supraventricular tachyarrhythmias (SVTs) and sinus tachycardias (STs).

While SVTs and STs have been reported to trigger 55%2 to 69%³ inappropriate shocks, PARAD®+ demonstrated a 99% overall specificity to these arrhythmias with out-of-the-box settings in a study recently published4, drastically reducing the number of inappropriate shocks.

OVATIO™ DR 6550 and OVATIO™ VR 6250 are our smallest dual chamber ICDs currently available (29cc).

PACEMAKERS: THE REPLY™ FAMILY

State-of-the-art pacemakers are like miniaturized computers capable of monitoring the heart's spontaneous activity. Sorin Group manufactures the world’s smallest pacemaker family: REPLY™.

REPLY™ pacemakers integrate the Sorin Group’s proprietary and exclusive SafeR™ pacing mode that constantly monitors the patient’s natural cardiac activity and reduces the amount of pacing delivered to the right ventricle, thereby promoting natural cardiac function.

SafeR™ reduces pacing in the ventricle to 0.1% in patients without heart block5. Furthermore, recently published results have shown that patients with different degrees of heart block may also benefit from this pacing mode6.

The SafeR™ technology builds on the Sorin Group’s proven SafeR™ mode, the first pacing mode designed to limit unnecessary ventricular pacing that was available in a pacemaker. SafeR™ was first launched in September 2003 in Europe and received FDA approval in May 2005 (Sorin Group was the first company to receive US market clearance for a pacemaker incorporating a pacing mode that minimizes ventricular pacing).

1 Brady pacing 0-145bpm, VT, FVT, VF – 100- >255bpm

6 Pioger G, Leny G., Nitzsche R; Ripart A. AAIsafeR Limits Ventricular Pacing in Unselected Patients. PACE 2007; 30: S66-S70)